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Abstract
Purpose—Nipple-sparing mastectomy, which may improve cosmesis, body image, and sexual 
function in comparison to non-nipple-sparing mastectomy, is increasingly used to treat early-stage 
breast cancer; however, long-term survival data are lacking. We evaluated survival after nipple-
sparing mastectomy versus non-nipple-sparing mastectomy in a population-based cancer registry.
Methods—We conducted an observational study using the California Cancer Registry, 
considering all stage 0–III breast cancers diagnosed in California from 1988 to 2013. We 
compared breast cancer-specific and overall survival time after nipple-sparing versus non-nipple-
sparing mastectomy, using multivariable analysis.
Results—Among 157,592 stage 0–III female breast cancer patients treated with unilateral 
mastectomy from 1988–2013, 993 (0.6 %) were reported as having nipple-sparing and 156,599 
(99.4 %) non-nipple-sparing mastectomies; median follow-up was 7.9 years. The proportion of 
mastectomies that were nipple-sparing increased over time (1988, 0.2 %; 2013, 5.1 %) and with 
neighborhood socioeconomic status, and decreased with age and stage. On multivariable analysis, 
nipple-sparing mastectomy was associated with a lower risk of breast cancer-specific mortality 
compared to non-nipple-sparing mastectomy [hazard ratio (HR) 0.71, 95 % confidence interval 
(CI) 0.51–0.98]. However, when restricting to diagnoses 1996 or later and adjusting for a larger set 
of covariates, risk was attenuated (HR 0.86, 95 % CI 0.52–1.42).
Conclusions—Among California breast cancer patients diagnosed from 1988–2013, nipple-
sparing mastectomy was not associated with worse survival than non-nipple-sparing mastectomy. 
These results may inform the decisions of patients and doctors deliberating between these surgical 
approaches for breast cancer treatment.
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Introduction
Despite randomized clinical trials demonstrating equivalent survival after breast conserving 
therapy versus mastectomy [1], use of mastectomy (specifically, contralateral prophylactic 
mastectomy) has risen recently [2]. This coincided with increased uptake of genetic testing 
for cancer risk assessment [3, 4], and with reports that prophylactic mastectomy reduces 
breast cancer risk among women with an inherited BRCA1/2 mutation [5]. Given evidence 
that mastectomy rates are rising, interest has grown in less invasive procedures such as 
nipple-sparing mastectomy (NSM) [6]. Compared to non-nipple-sparing mastectomy (non-
NSM), NSM may improve cosmesis, body image, and sexual function [7]. However, 
concerns remain about NSM’s safety with regard to breast cancer recurrence and survival. 
Randomized clinical trials do not exist and are unlikely to be initiated, and existing 
observational studies were limited to single centers or short follow-up time. We took 
advantage of the large population-based California Cancer Registry (CCR) to compare 
survival of stage 0–III female breast cancer patients treated with NSM versus non-NSM 
from 1988 to 2013.
Methods
The study population consisted of all female California residents diagnosed with a first 
primary breast cancer (International Classification of Disease for Oncology, 3rd Edition, site 
codes C50.0–50.9 and histologic codes: 8000, 8010, 8020, 8022, 8050, 8140, 8201–8230, 
8255, 8260, 8401, 8453, 8480–8525, and 8575), of American Joint Commission on Cancer 
stages 0–III, from January 1, 1988 to December 31, 2013. The analysis was overseen by the 
Institutional Review Board of the Cancer Prevention Institute of California. We obtained 
CCR information regarding patient and tumor characteristics, initial treatment course and 
patient vital status through December 31, 2013. We used an established measure of 
neighborhood socioeconomic status (SES) based on patients’ residence when diagnosed [8]. 
An initial surgical procedure of subcutaneous mastectomy, also called nipple-sparing 
mastectomy, was coded as NSM. Procedures of total (simple) mastectomy, modified radical 
mastectomy, radical mastectomy, or extended radical mastectomy (all without removal of 
uninvolved contralateral breast) and mastectomy NOS were coded as non-NSM. Survival 
time was measured in days from diagnosis to death. We used Cox proportional hazards 
regression to model associations with overall and breast cancer-specific mortality. Minimally 
adjusted models were stratified by stage and adjusted for age. Fully adjusted models were 
stratified by stage and histology; adjusted for age, race/ethnicity, tumor size, lymph node 
involvement, adjuvant chemotherapy and/or radiation, neighborhood SES, marital status, 
hospital characteristics (SES composition of patients and National Cancer Institute-
designated cancer center status), and diagnosis year; and adjusted for clustering by hospital. 
In secondary analyses limited to diagnoses in 1996 or later, for which more covariates were 
available, models were additionally adjusted for grade, estrogen receptor (ER)/progesterone 
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receptor (PR) status, and insurance status. We tested the proportional hazards assumption for 
each covariate using correlation tests of time versus scaled Schoenfeld residuals. The 
assumption was violated for stage and histology; thus, we conducted stratified Cox 
regression models allowing the baseline hazard to vary by these variables. We used SAS 
version 9.4 for all analyses.
Results
A total of 547,893 women were diagnosed with a first primary breast cancer in California 
from 1988 to 2013. Patients were excluded from analysis as follows: stage other than 0–III 
(69,078); diagnosis by death certificate or autopsy (80) or not microscopically confirmed 
(369); ineligible histologic type (8166); tumor size unknown, microscopic, diffuse, Paget’s 
or mammographic report only (42,118); surgery other than unilateral NSM or unilateral non-
NSM (262,789); subsequent breast tumor within 2 months of diagnosis (6174); bilateral 
synchronous breast cancer (20); invalid follow-up (37); or unknown cause of death (1470). 
After exclusions, 157,592 women were available for analysis, of whom 156,599 (99.4 %) 
underwent unilateral non-NSM and 993 (0.6 %) unilateral NSM. NSM use increased over 
time (1988, 0.2 %; 2013, 5.1 %) and with neighborhood SES, and decreased with age (Table 
1). The median follow-up was 7.9 years (interquartile range, 3.6–14.0 years) for all patients 
and for those who had non-NSM, compared to 1.9 years (interquartile range, 0.7–5.5 years) 
for patients who had NSM (Supplemental Table).
In both minimally and fully adjusted models, NSM was associated with lower breast cancer-
specific mortality than non-NSM (hazard ratio, HR 0.71, 95 % confidence interval, CI 0.51–
0.98 fully adjusted, Table 2). In a secondary analysis limited to diagnoses in 1996 or later, a 
decreased risk with NSM was seen in the minimally adjusted model (HR 0.61, 95 % CI, 
0.38–0.98), but the effect was attenuated in the fully adjusted model (HR 0.79, 95 % CI, 
0.48–1.30, data not shown), and further attenuated after adjusting for grade, ER/PR status, 
and insurance (HR 0.86, 95 % CI, 0.52–1.42).
In both minimally and fully adjusted models, NSM was not associated with overall mortality 
(Table 2). In a subset with diagnoses in 1996 or later, NSM was associated with lower 
overall mortality compared with non-NSM in a minimally adjusted model, but the effect was 
no longer significant after adjustment for all covariates.
Discussion
To the best of our knowledge, this is the largest population-based study of mortality among 
breast cancer patients treated with NSM compared to non-NSM, with longer median follow-
up (7.9 years) than previously reported. Consistent with prior studies [6, 9–14], we found no 
evidence of worse survival after NSM in this “real world” setting. In fact, NSM was 
associated with better survival than non-NSM; however, this association did not persist in a 
multivariable model adjusting for all clinical and sociodemographic factors, including grade, 
ER/PR status, and insurance status. NSM use increased over time, and was more prevalent 
among younger women who had earlier-stage cancer and/or resided in higher-SES neighbor-
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hoods. Thus, the better survival associated with NSM in the minimally adjusted model may 
reflect confounding by neighborhood SES.
Our study has limitations. Most notably, we had to restrict our assessment to patients having 
unilateral mastectomy, because SEER and other registries do not capture the nipple-sparing 
status of bilateral mastectomies. Given the benefits of prophylactic bilateral mastectomy for 
patients with hereditary breast cancer [5] and the growing interest in bilateral NSM as a less 
invasive approach for primary breast cancer prevention in high-risk women [13], comparing 
outcomes of bilateral NSM versus bilateral non-NSM would be clinically valuable. This 
limitation should be addressed by adding detail about nipple-sparing status to routinely 
collected registry data items regarding bilateral mastectomy. Other gaps in registry data 
include family history and inherited genetic mutation status; however, we would not expect 
major differences in hereditary risk between the two groups that received unilateral 
mastectomy. Another potential concern is the possibly differential coding of NSM by 
hospital cancer registrars, which could result in misclassification of some NSM as non-
NSM. There was differential follow-up time between patients who received non-NSM 
compared to NSM; however, the multivariable models that we used controlled for this 
difference. Moreover, results that included only the more recently diagnosed patients (1996–
2013) were similar to those of the full cohort (1988–2013), which offers evidence that our 
findings are robust to differences in follow-up time. Despite these limitations, however, our 
study offers considerable strengths: it encompasses the full and diverse population of 
California, minimizes selection bias and provides results that can be generalized broadly. In 
the absence of randomized clinical trials, our comprehensive observational study of 157,592 
breast cancer patients offers the best available evidence regarding the comparable survival 
between NSM and non-NSM.
Conclusion
Among California breast cancer patients diagnosed from 1988 to 2013, nipple-sparing 
mastectomy was not associated with worse survival than non-nipple-sparing mastectomy. 
These results may inform decisions of patients and doctors deliberating between these 
surgical approaches for breast cancer treatment.
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Refer to Web version on PubMed Central for supplementary material.
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